[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Johnson & Johnson (JNJ)

Johnson & Johnson (JNJ)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 579,826,368
  • Shares Outstanding, K 2,407,217
  • Annual Sales, $ 94,193 M
  • Annual Income, $ 26,804 M
  • EBIT $ 23,115 M
  • EBITDA $ 30,618 M
  • 60-Month Beta 0.26
  • Price/Sales 6.09
  • Price/Cash Flow 16.89
  • Price/Book 7.07

Options Overview Details

View History
  • Implied Volatility 24.86% (+0.09%)
  • Historical Volatility 19.32%
  • IV Percentile 88%
  • IV Rank 71.21%
  • IV High 29.89% on 03/27/26
  • IV Low 12.42% on 07/24/25
  • Expected Move (DTE 5) 4.54 (1.88%)
  • Put/Call Vol Ratio 0.62
  • Today's Volume 19,782
  • Volume Avg (30-Day) 26,741
  • Put/Call OI Ratio 0.91
  • Today's Open Interest 389,659
  • Open Int (30-Day) 353,768
  • Expected Range 236.33 to 245.41

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 25 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $2.83
  • Number of Estimates 7
  • High Estimate $2.88
  • Low Estimate $2.69
  • Prior Year $2.77
  • Growth Rate Est. (year over year) +2.17%

Price Performance

See More
Period Period Low Period High Performance
1-Month
220.84 +9.07%
on 06/01/26
241.60 -0.30%
on 06/11/26
+16.61 (+7.41%)
since 05/12/26
3-Month
220.37 +9.30%
on 05/11/26
247.21 -2.56%
on 04/02/26
-1.17 (-0.48%)
since 03/12/26
52-Week
149.04 +61.61%
on 06/20/25
251.71 -4.31%
on 03/02/26
+84.21 (+53.75%)
since 06/12/25

Most Recent Stories

More News
New TALVEY® (talquetamab-tgvs) plus DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) data demonstrate the strength of a bispecific combination in earlier-line relapsed or refractory multiple myeloma

STOCKHOLM , June 13, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ), a worldwide leader in multiple myeloma therapies, today announced results from the investigational Phase 3 MonumenTAL-3 study...

JNJ : 240.87 (+1.07%)
Johnson & Johnson Expands U.S. Availability of TECNIS PureSee IOL, an Advanced Lens Option for Cataract Surgeons and Patients

Expanded U.S. availability paired with new patient lifestyle quiz encourages informed decision-making ahead of cataract surgery. ...

JNJ : 240.87 (+1.07%)
IMAAVY® (nipocalimab-aahu) demonstrates durable hemoglobin response and rapid onset of effect in pivotal Phase 2/3 study in warm autoimmune hemolytic anemia (wAIHA), an autoantibody-driven disease with no FDA-approved therapies

STOCKHOLM , June 11, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today is presenting the first comprehensive results from the Phase 2/3 ENERGY study showing that IMAAVY ® (nipocalimab-aahu) produced a...

JNJ : 240.87 (+1.07%)
Tango Therapeutics (TNGX) Stock Soars on Pancreatic Cancer Trial Results

Tango Therapeutics shares rallied on Monday after recording impressive results for its pancreatic cancer drug. Here’s how you should play TNGX stock at current levels.

IDYA : 28.98 (+0.49%)
JNJ : 240.87 (+1.07%)
INCY : 108.53 (+0.65%)
TNGX : 30.94 (+3.76%)
RHHBY : 51.6500 (+0.58%)
Johnson & Johnson to Acquire Firefly Bio, Inc. to Expand Oncology Pipeline with Novel Degrader Antibody Conjugate Platform

Expands the Company’s expertise in targeting pan-KRAS and other drivers of hard-to-treat cancers Acquisition adds a proprietary degrader antibody conjugate...

JNJ : 240.87 (+1.07%)
Johnson & Johnson late-breaking results show nipocalimab significantly reduced systemic lupus erythematosus (SLE) disease activity in a Phase 2 study

LONDON , June 3, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced nipocalimab met the primary endpoint of decreasing disease activity at 24 weeks as measured by SLE Responder Index...

JNJ : 240.87 (+1.07%)
Johnson & Johnson presents new data further reinforcing the role of nipocalimab in lowering the autoantibodies driving Sjögren's disease

LONDON , June 3, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced new biomarker exploratory analyses from the Phase 2 DAHLIAS study evaluating nipocalimab in adults with moderate-to-severe...

JNJ : 240.87 (+1.07%)
Even If Eli Lilly Stock Continues to Shine, Stay Away from This Pharmaceutical ETF

The rest of the stocks in the IHE ETF make it an unappealing way to play the pharma industry here.

IHE : 94.75 (-0.34%)
JNJ : 240.87 (+1.07%)
LLY : 1,133.00 (-2.41%)
PPH : 106.47 (-0.68%)
$DOWI : 51,202.26 (+0.70%)
3 Dividend Kings That Earn Their Crown Every Quarter

These 3 Dividend Kings combine decades of dividend growth with strong fundamentals, recession resistance, and long-term income potential

JNJ : 240.87 (+1.07%)
BDX : 146.24 (-0.75%)
KVUE : 18.14 (+0.39%)
PEP : 144.27 (+0.38%)
RYBREVANT FASPROâ„¢ (amivantamab and hyaluronidase-lpuj) pivotal data show strong and durable responses in advanced head and neck cancer where options remain limited

CHICAGO , May 31, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced pivotal results from the Phase 1b/2 OrigAMI-4 study showing that subcutaneous amivantamab and hyaluronidase-lpuj...

JNJ : 240.87 (+1.07%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Johnson & Johnson's biggest strength is its diversified business model. It operates through pharmaceuticals, medical devices and consumer products divisions. Its diversification helps it to withstand economic cycles more effectively. J&J has one of the largest research and development (R&D) budget among...

See More

Key Turning Points

3rd Resistance Point 245.40
2nd Resistance Point 243.16
1st Resistance Point 242.01
Last Price 240.87
1st Support Level 238.62
2nd Support Level 236.38
3rd Support Level 235.23

See More

52-Week High 251.71
Last Price 240.87
Fibonacci 61.8% 212.49
Fibonacci 50% 200.38
Fibonacci 38.2% 188.26
52-Week Low 149.04

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.